PMID- 25115353
OWN - NLM
STAT- MEDLINE
DCOM- 20150701
LR  - 20221207
IS  - 1440-1681 (Electronic)
IS  - 0305-1870 (Linking)
VI  - 41
IP  - 10
DP  - 2014 Oct
TI  - KCNJ11 E23K variant is associated with the therapeutic effect of sulphonylureas 
      in Chinese type 2 diabetic patients.
PG  - 748-54
LID - 10.1111/1440-1681.12280 [doi]
AB  - The aim of the present study was to investigate the effect of the E23K variant of 
      the potassium inwardly rectifying channel, subfamily J, member 11 (KCNJ11) gene 
      on gliclazide modified release (MR) treatment in newly diagnosed patients with 
      type 2 diabetes mellitus (T2DM). A total of 108 diabetic patients with no history 
      of antidiabetic medication was treated with gliclazide MR for 16 weeks and 
      underwent follow up at Weeks 2, 4, 8, 12 and 16. All patients were genotyped for 
      KCNJ11 E23K (rs5219). At baseline, patients with the KK genotype had higher blood 
      glucose and lower serum insulin levels after oral glucose administration than 
      patients with the EE and EK genotypes (P < 0.05 for all). During treatment, 
      individuals with the KK genotype had lower fasting glucose levels and were more 
      likely to attain the target fasting glucose level (Plog rank  = 0.028) than E 
      allele carriers. Patients with the KK genotype had larger augmentations in 
      changes (Delta) in acute insulin response (P = 0.049) and Delta body mass index 
      (P = 0.003). Moreover, patients with the EK genotype had a lower variance in 
      changes in fasting insulin levels (P = 0.049) and homeostasis model assessment of 
      beta-cell function (P = 0.021) than those with the KK genotype. The findings of the 
      present study suggest that the KCNJ11 E23K variant is associated with a greater 
      effect of sulphonylurea treatment in newly diagnosed Chinese patients with T2DM.
CI  - (c) 2014 Wiley Publishing Asia Pty Ltd.
FAU - Li, Qing
AU  - Li Q
AD  - Department of Endocrinology and Metabolism, Shanghai Diabetes Institute, Shanghai 
      Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Clinical Center 
      of Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes 
      Mellitus, Shanghai, China.
FAU - Chen, Miao
AU  - Chen M
FAU - Zhang, Rong
AU  - Zhang R
FAU - Jiang, Feng
AU  - Jiang F
FAU - Wang, Jie
AU  - Wang J
FAU - Zhou, Jian
AU  - Zhou J
FAU - Bao, Yuqian
AU  - Bao Y
FAU - Hu, Cheng
AU  - Hu C
FAU - Jia, Weiping
AU  - Jia W
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Kir6.2 channel)
RN  - 0 (Potassium Channels, Inwardly Rectifying)
RN  - 0 (Sulfonylurea Compounds)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Alleles
MH  - Asian People/*genetics
MH  - Diabetes Mellitus, Type 2/*drug therapy/*genetics/metabolism
MH  - Female
MH  - Genetic Variation/*genetics
MH  - Genotype
MH  - Glucose/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin-Secreting Cells/drug effects
MH  - Male
MH  - Middle Aged
MH  - Potassium Channels, Inwardly Rectifying/*genetics
MH  - Sulfonylurea Compounds/*therapeutic use
OTO - NOTNLM
OT  - KCNJ11
OT  - pharmacogenetics
OT  - sulphonylureas
OT  - type 2 diabetes
EDAT- 2014/08/15 06:00
MHDA- 2015/07/02 06:00
CRDT- 2014/08/14 06:00
PHST- 2014/03/04 00:00 [received]
PHST- 2014/06/06 00:00 [revised]
PHST- 2014/06/16 00:00 [accepted]
PHST- 2014/08/14 06:00 [entrez]
PHST- 2014/08/15 06:00 [pubmed]
PHST- 2015/07/02 06:00 [medline]
AID - 10.1111/1440-1681.12280 [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 2014 Oct;41(10):748-54. doi: 10.1111/1440-1681.12280.